Ventaris Surgical, a San Carlos, California-based medical device company, has raised $30 million in a Series A financing to advance a new ureteroscopic system designed to improve stone clearance during kidney stone procedures.
The round was led by Longitude Capital, with participation from new investor Vensana Capital and existing backers Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners. As part of the financing, Longitude Capital’s Varun Gupta and Vensana Capital’s Justin Klein will join Ventaris’ board of directors, alongside independent board member Amir Abolfathi.
Ventaris is developing a ureteroscopic platform aimed at helping surgeons achieve more complete stone clearance, a persistent challenge in a procedure area that is among the most common interventions in urology. The company said outcomes can vary due to factors such as patient anatomy, stone burden, workflow constraints, and surgeon fatigue—variables that can make consistent, complete removal difficult with existing tools.
Ventaris said the new capital will be used to support continued clinical development and to advance regulatory and commercial milestones.
The company also noted that an earlier version of its announcement contained incorrect contact information.
KEY QUOTES:
“Ventaris’ technology has the potential to both improve outcomes and reduce the burden on surgeons. Their approach resolves several critical unmet needs in today’s standard of care.”
Maxwell Bikoff, Managing Director, Longitude Capital
“Kidney stone surgery demands an exceptional level of skill, focus, and persistence. Surgeons are often willing to invest the time and effort required to pursue complete stone clearance, but today’s tools can make that goal difficult to achieve consistently. Ventaris was founded with the goal of removing unnecessary friction from the procedure, so that surgeons can focus their time and effort on reliably achieving complete stone clearance. We are excited to embark on this next phase of growth with Longitude Capital and Vensana Capital.”
Surag Mantri, CEO, Ventaris Surgical
